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Abstract
Background: Early diagnosis is crucial for management of patients with suspected acute myocardial infarction (AMI). Among innovative and pro-
mising biomarkers, the recent interest raised on glycogen phosphorylase isoenzyme BB (GPBB) has prompted us to perform a meta-analysis of pu-
blished studies.
Materials and methods: A systematic electronic search was carried out on PubMed, Web of Science and Google Scholar, with no date restriction, 
to retrieve all articles that have investigated the early diagnostic performance of GPBB in patients with suspected AMI, and directly reported or 
allowed calculation of sensitivity and specifi city. A meta-analysis of the reported sensitivity and specifi city of each study and pooled area under the 
curve (AUC) was then performed by random eff ect approach. Heterogeneity was assessed by I-square statistics.
Results: Eight studies were fi nally selected for analysis (941 subjects; 506 cases and 435 controls), with a high heterogeneity (I-squared, 86.3%). 
The resulting pooled estimates and 95% confi dence interval were 0.854 (0.801-0.891) for sensitivity, 0.767 (0.713-0.815) for specifi city, 0.826 (0.774-
0.870) for negative predictive value, 0.802 (0.754-0.844) for positive predictive value, and 0.754 (0.602-0.907) for AUC. In those studies that have 
simultaneously assessed GPBB and a troponin immunoassay, the combination of these biomarkers did not signifi cantly improve the performance of 
troponin alone.
Conclusion: GPBB does not meet the current requirements for an effi  cient diagnosis of AMI when used as a stand-alone test, whereas its combina-
tion with troponin merits further investigation in larger trials.
Key words: myocardial infarction; ischemic heart disease; glycogen phosphorylase isoenzyme BB; GPBB
Received: August 08, 2012 Accepted: October 22, 2012
Glycogen phosphorylase isoenzyme BB in the diagnosis of acute myocardial 
infarction: a meta-analysis
Giuseppe Lippi*1, Camilla Mattiuzzi2, Ivan Comelli3, Gianfranco Cervellin3
1Unità Operativa Diagnostica Ematochimica, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero-Universitaria 
di Parma, Parma, Italy
2Servizio Governance Clinica, Ospedale di Trento, Trento, Italy
3Unità Operativa Pronto Soccorso e Medicina d’Urgenza, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
*Corresponding author: glippi@ao.pr.it, ulippi@tin.it
Original paper
Introduction
Acute myocardial infarction (AMI) is the most dis-
abling and deadly disease in western countries, 
causing ~15% of all deaths in the United States, ac-
cording to the recent statistics of the American 
Heart Association (1). An early diagnosis (i.e., within 
3 to 6 hours from onset of the symptoms) and an 
effi  cient risk stratifi cation are crucial for manage-
ment of patients with suspected acute coronary 
syndrome, since eff ective myocardium salvage is 
only achieved when revascularization is estab-
lished within 6 hours from onset of the symptoms. 
An effi  cient triage is also essential to face the con-
stant overcrowding of emergency departments 
(EDs), which inherently causes inadequate quality 
of care and patient distress (2). Beyond consolidat-
ed use of troponin testing, which is the biochemi-
cal gold standard in the diagnostic approach of 
patients with suspected AMI, there is spasmodic 
research on additional biomarkers that would en-
able fast and appropriate triage of patients in the 
ED, as well as in the coronary care unit (CCU) (3,4). 
Among innovative and promising biomarkers of 
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AMI, the development of commercial immunoas-
says has contributed to renew the interest on gly-
cogen phosphorylase isoenzyme BB (GPBB).
GPBB is a fundamental enzyme in the regulation 
of carbohydrate metabolism by mobilization of 
glycogen. Three diff erent isoenzymes exist; glyco-
gen phosphorylase isoenzyme MM (GPMM) is 
prevalently contained in human skeletal muscle, 
glycogen phosphorylase isoenzyme LL (GPLL) is 
contained in liver and all other tissues except heart, 
skeletal muscle, and brain, whereas GPBB is pre-
dominantly produced by brain and heart, wherein 
the 94 kD monomer is present in comparable tis-
sue concentration (5). A serum increase of GPBB 
should hence be highly specifi c for myocardial in-
jury when damage to the brain and consequent 
perturbation of blood-brain barrier has been ruled 
out.
The very fi rst evidence of GPBB testing in patients 
with AMI was provided more than 25 years ago by 
Rabitzsch et al., who showed that this biomarker is 
rapidly released into the circulation in the early 
phase of AMI (6,7). These preliminary fi ndings 
paved the way to a series of further trials. In a re-
cent article published in this journal, Cubranic et 
al. concluded that GPBB may contribute to early 
diagnosis of ischemic heart disease, with sensitivi-
ty of 0.97 and specifi city of 0.81 in patients with 
AMI admitted within 3 hours from onset of the 
symptoms (8). These interesting results prompted 
us to perform a meta-analysis of published studies 
that have assessed the diagnostic performance of 
GPBB in patients with suspected AMI.
Materials and methods
Search methodology
We carried out a systematic electronic search on 
the three most accessed scientifi c databases (i.e., 
PubMed, Web of Science and Google Scholar) (9), 
with no date restriction, to retrieve all articles that 
have investigated the early diagnostic perfor-
mance (i.e., within 6 hours from the onset of the 
symptoms) of GPBB in trials with a sample size of 
not less than 20 patients with suspected AMI. The 
following keywords were used: “myocardial infarc-
tion” or “ischaemic heart disease” “or “acute coro-
nary syndrome”, in combination with “glycogen 
phosphorylase isoenzyme BB” or “GPBB” or “GP-
BB”. The bibliographic references of the articles 
published in English, French, Spanish and Italian 
were reviewed for additional relevant studies. All 
the articles identifi ed according to these search 
criteria were systematically assessed for quality by 
two authors (GL and GC), according to the Quality 
Assessment of Diagnostic Accuracy Studies (QUA-
DAS) checklist criteria (10). Disagreements were re-
solved by a third opinion (CM). After careful read-
ing of abstract and text, only articles directly re-
porting or allowing calculation on a 2×2 contin-
gency table of sensitivity and specifi city according 
to accuracy data in combination with prevalence 
and sample size were deemed eligible for meta-
analysis. When multiple time points were available, 
we limited the extraction to data of the earliest 
sampling (i.e., within 6 hours). Abstracts, review ar-
ticles, and/or lecture presentations, as well as arti-
cles that were not fulfi lling the aforementioned 
criteria were discarded. The number of patients 
with a true-positive, false-positive, false-negative 
and true-negative test results of GPBB in patients 
with suspected AMI was extracted, along with in-
formation on assays used and cohort enrolled.
Statistical analysis
Heterogeneity was assessed by the chi-square 
based statistics and I-square test, wherein thresh-
olds of 25%, 50% and 75% designate low, moder-
ate, and high heterogeneity (11). The cumulative 
estimates and 95% confi dence interval (95% CI) of 
sensitivity, specifi city, negative predictive value 
(NPV) and positive predictive value (PPV) were fur-
ther calculated using a random eff ect model for I-
square values greater than 50%. The area under 
the receive operator characteristic (ROC) curve 
(AUC) values with 95% CI weighted for sample size 
were pooled according to Higgins et al. (11). Statis-
tical analysis was performed with MedCalc Version 
12.3.0 (MedCalc Software, Mariakerke, Belgium).
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Results
The electronic search according to the above men-
tioned criteria identifi ed 45 citations of studies and 
abstracts after elimination of replicates among the 
three searchable databases. Thirty six studies were 
excluded after abstract and/or full text reading be-
cause GPBB was not assessed in the setting of AMI 
diagnostics. The remaining nine studies were care-
fully assessed for quality after revision of the full 
text, and one was excluded because it did not con-
tain suffi  cient information for calculating either 
the pooled AUC, or the pooled estimates of sensi-
tivity and specifi city. Inter-rater reliability was ex-
cellent (k = 0.93; P < 0.001).
Overall, eight studies were fi nally selected for anal-
ysis, all containing complete data for calculating 
the pooled AUC, whereas only seven provided suf-




admission 4.7 h 
after chest pain
107 62 45 In-house immunoassay 7 0.91 0.81 0.93
Peetz,
2005
ED admission <2 




admission 3.8 h 
after chest pain




admission 3.2 h 
after chest pain




admission <4 h 
after chest pain
354 198 156 Diacordon 7 0.63 0.64 -
Bozkurt,
2011
ED admission <1 h 
after chest pain 72 48 24 Diacordon 10 0.82 0.96 0.44
Meune, 
2011
ICU admission <6 
h after chest pain 60 31 29 Diacordon 10 0.55 0.50 0.64
Cubranic, 
2012
CCU admission <3 
h after chest pain 92 71 21 Diacordon 7 0.93 0.97 0.81





* Pooled estimate and 95% Confi dence Interval
ED - Emergency Department; ICU - Intensive Care Unit; CCU - Coronary Care Unit; AUC - area under the Receiver Operating 
Characteristic (ROC) curve.
TABLE 1. Studies that have assessed the diagnostic performance of glycogen phosphorylase isoenzyme BB (GPBB) for diagnosis of 
acute myocardial infarction (AMI).
fi cient information for calculating the cumulative 
sensitivity, specifi city, NPV and PPV (Table 1) (8,12-
18). The eight studies (mean quality score, 10.3) to-
taled 941 subjects (506 AMI cases and 435 con-
trols). The between-study variation was high and 
attributable to heterogeneity (chi-squared, 58.40; 
DF, 8; I-squared, 86.3%; P < 0.001). In 5 out of 8 
studies (62%) the setting was the ED, whereas pa-
tients were directly admitted to the CCU in two 
studies, and to the intensive care unit in one trial. 
GPBB was assayed with the Diacordon® GPBB–ELI-
SA test (Diagenics, Woburn, MA, USA) in six stud-
ies, whereas it was measured with Evidence® Car-
diac Panel (RANDOX Laboratories Ltd., United 
Kingdom) and in-house developed immunoassay 
in the remainders. The diagnostic threshold of 
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GPBB was comparable across the studies, being 
comprised between 7 and 10 μg/L. The diagnostic 
performances of the eight studies as well as the 
pooled data are shown in Table 1. The pooled esti-
mates and 95% confi dence intervals were 0.854 
(0.801-0.891) for sensitivity, 0.767 (0.713-0.815) for 
specifi city, 0.826 (0.774-0.870) for NPV and 0.802 
(0.754-0.844) for PPV. The AUCs of the eight single 
studies as well as the pooled AUC (0.754 [0.602-
0.907]) are shown in Figure 1.
those of the current high-sensitive immunoassays, 
which are typically characterized by AUCs of ~0.96, 
sensitivity greater than 0.85, NPV greater than 0.99 
and specifi city values comprised between 0.80 
and 0.93 (19). No one of the pooled estimates of 
GPBB outweighed or even approximated these ex-
cellent diagnostic performances. The lowest esti-
mate of GPBB was obtained for specifi city, but this 
is not surprising inasmuch as the concentration of 
this biomarker is infl uenced by skeletal muscle in-
jury, as clearly shown by Lippi et al. who reported a 
signifi cant post-exercise GPBB increase of ~40% 
after a 21-km run in trained athletes (20). The as-
sessment of the article of Figiel et al., which had 
been originally excluded from our meta-analysis 
due to the lack of a reference group which did not 
allow to gather information on specifi city and AUC, 
also revealed a poor sensitivity (i.e., 0.47) of GPBB 
in 20 patients with AMI, in whom the biomarker 
had been assessed < 3 hours from the onset of the 
symptoms (21). It is noteworthy, however, the four 
studies that enrolled the patients within 1 to 3 
hours from the onset of chest pain showed a much 
better sensitivity (0.96-1.0) than the remainders, 
and this is attributable to early release of GPBB due 
to burst in glycogenolysis and a concomitant in-
crease in plasma membrane permeability that both 
occur immediately after myocardial ischemia (5).
In those studies that have simultaneously assessed 
GPBB and a troponin immunoassay (14,16,18), their 
combination (either marker positive) did not sig-
nifi cantly improve the performance of troponin 
alone. For example, Meune et al. reported an AUC 
of 0.842 for troponin alone versus 0.854 for the 
combination (P = 0.728) (18). Even more interest-
ingly, in the study of Mion et al., the diagnostic ef-
fi cacy of troponin alone was even greater than 
that combining troponin and GPBB (83.3 versus 
69.7%) (14). We thereby conclude that GPBB does 
not met the current requirements for an effi  cient 
diagnosis of AMI when used as a stand-alone test, 
whereas its combination with troponin merits fur-
ther investigation in larger trials.
Potential confl ict of interest
None declared.
FIGURE 1. Diagnostic performance of glycogen phosphorylase 
isoenzyme BB (GPBB) for diagnosis of acute myocardial infarc-
tion (AMI).
Area under the receiver operating characteristic (ROC) curve 
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Discussion
Only a few reliable studies have been published so 
far on the potential role of GPBB as a stand-alone 
test in the triage approach of patients with sus-
pected ischaemic heart disease. Although the out-
come of some of these was promising, showing 
excellent values of sensitivity and specifi city, the 
results of others were instead disappointing (Table 
1). Regardless of the broad heterogeneity that we 
found across the studies included in this meta-
analysis, our results clearly attest that the diagnos-
tic performance of GPBB are much lower than 
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